Abstract：Objective To explore the efficacy and safety of Risenatide in the treatment of mild cognitive impairment in elderly patients with type 2 diabetes mellitus. Methods A total of 82 elderly patients with type 2 diabetes mellitus and mild cognitive impairment admitted to Huaian Cancer Hospital, Jiangsu Province from April 2019 to April 2021 were selected and divided into experimental group and control group according to the treatment plan. The control group (41 cases) was treated with insulin injection, and the experimental group (41 cases) was treated with Risenatide on the basis of the control group. The blood glucose, cognitive function, and neurological function index were compared between the two groups after 12 weeks of treatment, and the incidence of adverse reactions was recorded. Results The levels of glycosylated hemoglobin, fasting blood glucose before breakfast, and 2 h postprandial blood glucose in the two groups after treatment were lower than those before treatment, and those in the experimental group were lower than those in the control group (P ＜ 0.05). After treatment, the scores of Montreal cognitive assessment scale in the two groups were higher than those before treatment, the scores of National Institutes of Health stroke scale in the two groups were lower than those before treatment, and the scores of Montreal cognitive assessment scale in the experimental group were higher than those in the control group, and the scores of National Institutes of Health stroke scale were lower than those in the control group (P ＜ 0.05). After treatment, the levels of serum central nervous specific protein (S100β) and plasma β-amyloid protein-42 in the two groups were lower than those before treatment, and the experimental group was lower than the control group (P ＜ 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion The application of Risenatide in the treatment of mild cognitive impairment in elderly patients with type 2 diabetes mellitus can contribute to lower blood glucose level and improve cognitive function with good safety.
朱平 吴新华 马立明 严妍 时雯 余涛 黄玉杰 周洁▲. 利司那肽治疗老年2型糖尿病轻度认知功能障碍的效果及安全性[J]. 中国医药导报, 2022, 19(30): 79-82.
ZHU Ping WU Xinhua MA Liming YAN Yan SHI Wen YU Tao HUANG Yujie ZHOU Jie▲. Efficacy and safety of Risenatide in the treatment of mild cognitive impairment in elderly patients with type 2 diabetes mellitus. 中国医药导报, 2022, 19(30): 79-82.
京公网安备 11010502046598号